GlassScriptPhysician profile
Jeffrey Michael Jacobs
NPI 1912081746
$2,109.45
in general payments reported to CMS, 2019-2025
13 companies · $1,051 in 2025
The $1,051 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.86 · 2022: $21.95 · 2023: $277 · 2024: $745 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048 · Education: $25.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.54 |
| Education | $25.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $619.27 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $276.14 | 2023-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $259.13 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.84 | 2023-2025 | Hyqvia, Takhzyro, Glassia |
| Celltrion USA INC. | $124.06 | 2025 | Vegzelma |
| Novartis Pharmaceuticals Corporation | $121.66 | 2024-2025 | |
| Amgen INC. | $110.65 | 2023-2025 | Tezspire |
| Optinose US, INC. | $103.37 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $91.20 | 2024-2025 | Dupixent |
| Csl Behring | $78.47 | 2025 | Hizentra, Haegarda, Andembry |
| Ars Pharmaceuticals Operations, INC. | $53.53 | 2025 | Neffy |
| Genentech USA, INC. | $21.95 | 2022 | |
| Alk-Abello, INC | $20.18 | 2023 | Odactra, Ragwitek, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.